Σύγκριση μεθόδων

	Δοκιμή Ισοδυναμίας / Μη Κατωτερότητας	Τυχαιοποιημένη Ελεγχόμενη Δοκιμή (ΤΕΔ)	Σχεδιασμός διαδοχικών / ομαδικών διαδοχικών δοκιμών
Πεδίο	Πειραματικός Σχεδιασμός	Πειραματικός Σχεδιασμός	Πειραματικός Σχεδιασμός
Οικογένεια	Hypothesis test	Hypothesis test	Hypothesis test
Έτος προέλευσης	1987	1948	1979
Δημιουργός	Schuirmann, D.J. / EMA regulatory framework	James Lind (early precursor, 1747); modern formulation: Austin Bradford Hill & Medical Research Council (1948)	O'Brien & Fleming; Pocock; Lan & DeMets
Τύπος	Parametric equivalence / non-inferiority test	Interventional comparative study	Adaptive stopping trial design
Θεμελιώδης πηγή	Schuirmann, D.J. (1987). A Comparison of the Two One-Sided Tests Procedure and the Power Approach. Journal of Pharmacokinetics and Biopharmaceutics, 15(6), 657–680.	Schulz, K.F., Altman, D.G., Moher, D., for the CONSORT Group (2010). CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. BMJ, 340, c332.	O'Brien, P.C. & Fleming, T.R. (1979). A Multiple Testing Procedure for Clinical Trials. Biometrics, 35(3), 549–556.
Εναλλακτικές ονομασίες	non-inferiority trial, bioequivalence study, active-control trial, Denklik ve Üstünlük Olmayan Çalışma (Equivalence / Non-Inferiority)	RCT, randomised controlled trial, clinical trial, Randomize Kontrollü Çalışma (RCT) Tasarımı	group sequential design, adaptive stopping design, Ardışık Deneme Tasarımı (Sequential / Group Sequential)
Συναφείς	6	7	3
Σύνοψη	An equivalence or non-inferiority trial is a clinical study design that tests whether a new intervention is clinically equivalent to, or no worse than, an established standard by a pre-specified margin. Codified in Schuirmann's 1987 Two One-Sided Tests (TOST) framework and embedded in EMA and FDA regulatory guidance, this design is the regulatory standard for generic drug approval and medical device testing.	A randomized controlled trial (RCT) is the gold standard experimental design in clinical and health research, in which participants are randomly allocated to a treatment group or a control group so that the effect of an intervention can be measured with the highest possible degree of internal validity. The modern parallel-group RCT was formalized by Austin Bradford Hill and the Medical Research Council in their landmark streptomycin trial of 1948, and its reporting is governed today by the CONSORT 2010 guidelines (Schulz et al., 2010).	Sequential and group sequential trial designs allow a study to be stopped early — or continued — based on interim analyses conducted as data accumulate. The core framework was formalised by O'Brien and Fleming in 1979 and extended by Lan and DeMets's alpha-spending approach, and it controls the overall Type I error rate across all planned looks by pre-specifying both efficacy and futility boundaries before enrolment begins.